Medically reviewed by Hemal Patel, PhD, Professor of Anesthesiology at UC San Diego School of Medicine. UCSD profile.
Written and reviewed by the MeScreen UK editorial team.
If you have been told that your cholesterol is acceptable, yet your father had a heart attack at 49 or your sister needed early cardiac treatment despite doing many things right, you may already have met the limits of routine screening. Standard lipid panels are useful, but they do not capture every inherited contributor to cardiovascular risk.
Lipoprotein(a), usually written as Lp(a), sits in that gap. It is an LDL-like particle with an additional apolipoprotein(a) attached to it, and higher levels are associated with a greater risk of atherosclerotic cardiovascular disease and calcific aortic valve disease.[1][2] Importantly, Lp(a) is mostly genetically determined. You do not generally earn it through a poor lunch.
That is why the marker can be useful. It helps explain why two people with similar standard cholesterol results do not always carry the same long-term risk.
What Lp(a) actually measures
Lp(a) is structurally similar to LDL, the familiar low-density lipoprotein particle, but it carries an added protein called apolipoprotein(a). This matters because that extra component appears to contribute to pro-atherogenic and pro-inflammatory behaviour, and possibly to thrombosis-related mechanisms as well.[1][3]
In plain English, Lp(a) is not just another cholesterol number. It is a specific inherited lipoprotein particle associated with vascular risk. Levels are largely set by genetics, remain relatively stable through adult life, and are much less responsive to day-to-day lifestyle changes than markers such as triglycerides or HbA1c.
Why clinicians pay attention to it
Cardiovascular prevention works best when the estimate of risk is reasonably complete. If a marker is strongly inherited, stable over time, and linked to important outcomes, it can be genuinely useful even if it is not part of routine universal screening.
Consensus statements from European and international groups increasingly support measuring Lp(a) at least once in adult life, particularly because a single result may identify a meaningful inherited risk burden that standard testing misses.[2][3] In practice, it becomes especially relevant when there is premature cardiovascular disease in the family, unexplained high risk despite acceptable LDL cholesterol, or a need to refine how aggressively the rest of the risk profile should be managed.
This is not a case for biomarker tourism. It is a case for better context.
Where Lp(a) sits in the NHS and private-testing landscape
Routine NHS cardiovascular risk assessment quite reasonably focuses on established, scalable measures such as blood pressure, smoking status, diabetes risk, non-HDL cholesterol, and overall risk calculators. Public systems have to prioritise tests that are broadly actionable across very large populations.
That means Lp(a) often falls into the category of selective rather than routine testing. If there is a clear family history or a specialist reason, it may be considered. If you are a generally well person trying to understand inherited risk more proactively, private testing can sometimes fill that gap. That is the same prevention-space tension we described in our guide to preventative tests the NHS does not usually offer.
Private testing is useful only if the result changes understanding. On Lp(a), it often does.
Who might consider an Lp(a) test
Not everyone needs a long biomarker list. But Lp(a) may be worth discussing when:
- there is a family history of early heart attack, stroke, or unexplained cardiovascular disease,
- a close relative has known high Lp(a),
- standard cholesterol looks acceptable but the family story does not,
- there is established cardiovascular disease without an obvious explanation from traditional factors alone,
- you want a fuller baseline before making prevention decisions.
It also has value because it usually does not need repeating often. Since levels are largely genetic and fairly stable, one good-quality measurement may be enough for many people unless the clinical picture changes or assay interpretation needs clarifying.
What a raised result actually means, and what it does not
A raised Lp(a) does not mean an event is inevitable. It means inherited risk may be higher than routine testing suggests. The sensible response is not panic. It is sharper management of the things you can influence: LDL-related burden, blood pressure, smoking, body composition, glucose control, exercise consistency, and overall cardiometabolic health.
This is where people sometimes get disappointed. Because Lp(a) is so genetic, ordinary lifestyle changes may not lower the number dramatically. That does not make lifestyle irrelevant. Quite the opposite. If one risk factor is relatively fixed, it becomes more important to optimise the other modifiable ones well.
Depending on age, personal history, and family context, some people may benefit from formal clinician review, more detailed lipid assessment, or discussion of treatment thresholds that take inherited risk more seriously.
Why Lp(a) should be read alongside other markers
Lp(a) is useful on its own only up to a point. It becomes more informative when read with ApoB, LDL-related markers, inflammatory measures, glucose regulation, and the broader clinical picture. A person with raised Lp(a), elevated ApoB, hypertension, and a strong family history has a different prevention conversation from someone whose only issue is an isolated inherited Lp(a) elevation.[2][4]
That is why single-marker obsessiveness tends to disappoint. Better prevention usually comes from joining the dots properly. If you are using MeScreen resources to understand broader health signals, pages like Mitochondrial Health, Scientific Studies, and How MeScreen works are useful because they encourage a systems view rather than a number-chasing one.
The sober bottom line for UK patients
Lp(a) is one of the more defensible extra tests because it can reveal inherited cardiovascular risk that standard panels understate. It is especially relevant when the family history looks more worrying than the routine numbers.
It should not replace NHS care, and it should not be interpreted theatrically. But it can be a very sensible one-time measurement for adults who want a clearer picture of why risk may run in families, and what that should mean for the rest of their prevention strategy.
Medically reviewed by Hemal Patel, PhD
Professor of Anesthesiology at UC San Diego School of Medicine, with research interests in mitochondrial biology, caveolin signalling and cellular bioenergetics.
Read Hemal Patel's MeScreen reviewer profile · Verify on UCSD Profiles
Better prevention starts with fewer blind spots.
If you are looking beyond basic screening, the aim is simple: clearer context, calmer interpretation, and decisions grounded in evidence rather than wellness theatre.
Frequently asked questions
What does lipoprotein(a) actually measure?
Lipoprotein(a), or Lp(a), is an LDL-like particle with an added apolipoprotein(a) component. Higher levels are associated with increased atherosclerotic cardiovascular risk and are largely genetically determined.
Is Lp(a) checked routinely on the NHS?
Not as a universal screening test for all adults. It may be checked selectively, especially when family history or unexplained early cardiovascular disease suggests inherited risk may be relevant.
Can you lower Lp(a) with diet and exercise alone?
Lifestyle still matters for overall cardiovascular risk, but Lp(a) itself is mostly inherited and often changes little with ordinary diet or exercise measures. Management usually focuses on improving the rest of the risk profile and, in some cases, specialist review.
Should Lp(a) be interpreted on its own?
No. It is best interpreted with LDL-related markers, blood pressure, smoking status, glucose control, family history, and overall clinical context. A raised Lp(a) informs the conversation, but it is not the whole conversation.
References
- Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853. doi:10.1093/eurheartj/ehq386.
- Mach F, Baigent C, Catapano AL, et al. 2023 ESC Guidelines for the management of cardiovascular disease prevention in clinical practice. Eur Heart J. 2024;45(38):4171-4319. doi:10.1093/eurheartj/ehae236.
- Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. Atherosclerosis. 2022;349:107-118. doi:10.1016/j.atherosclerosis.2022.03.021.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2024;9(3):250-258. doi:10.1001/jamacardio.2023.5403.
- NHS. NHS Health Check. Available at: https://www.nhs.uk/tests-and-treatments/nhs-health-check/